Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  The Lancet Oncology

• Publication date

  2012-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(12)70269-3PMID 22805292PMCID PMC4109286
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

  2012cited by this paper
• Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

  2012cited by this paper
• Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

  2012cited by this paper
• Mutation and copy number detection in human cancers using a custom genotyping assay.

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

  2011cited by this paper
• Resistance to MEK Inhibitors: Should We Co-Target Upstream?

  2011cited by this paper
• Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

  2011cited by this paper
• Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

  2011cited by this paper
• Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

  2011cited by this paper
• RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Mutations in GNA11 in uveal melanoma.

  2010cited by this paper
• Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

  2010cited by this paper
• Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

  2010cited by this paper
• RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

  2010cited by this paper
• MEK1 mutations confer resistance to MEK and B-RAF inhibition

  2009cited by this paper
• Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.

  2008cited by this paper
• Frequent somatic mutations of GNAQ in uveal melanoma and blue nevi

  2008cited by this paper
• AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study.

  2008cited by this paper
• Management of cutaneous melanoma.

  2004cited by this paper
• Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

  2004cited by this paper
• Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

  2004cited by this paper
• The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

  2004cited by this paper
• Common Terminology Criteria for Adverse Events v3.0 (CTCAE)

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin.

  1998cited by this paper
• Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts.

  1994cited by this paper

• Uveal Melanoma Treatment: An Update.

  2026cites this paper
• Melanoma: Pathogenesis and Targeted Therapy

  2026cites this paper
• Clinical Molecular Pathology and Treatment Developments in Advanced Uveal Melanoma: State of the Art

  2026cites this paper
• Dissecting the MAPK signaling landscape in malignant melanoma: from BRAF and NRAS mutations to precision combination therapies

  2026cites this paper
• Recurrent Melanoma in a Patient with Chronic Lymphocytic Leukemia (CLL) Presenting with an Apparent Co-Existing NRAS and BRAF Mutation: A Diagnostic and Treatment Conundrum

  2025cites this paper
• Exploiting Synthetic Lethality of PRMT5 for Precision Treatment of MTAP-Deficient Glioblastoma

  2025cites this paper
• Association Between miR-539 and miR-6824 and Their Target Gene, MAP2K1, Expression Level in Oral Cancer

  2025cites this paper
• Clinical features, treatment and outcomes of dabrafenib-associated uveitis

  2025cites this paper
• Unraveling Resistance Mechanisms to Gαq Pathway Inhibition in Uveal Melanoma: Insights from Signaling-Activation Library Screening

  2025cites this paper
• Reprogramming the Course of Precancer with Targeted Therapeutic Intervention: Lessons from Interception in Gastric Preneoplasia.

  2025cites this paper
• Mono or Di? A Potential-Controlled Electrochemical Halogenation of Anilines.

  2025cites this paper
• Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies

  2025influential citation
• Feasibility of multiomics tumor profiling for guiding treatment of melanoma

  2025cites this paper
• Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma

  2025cites this paper
• Targeting the MAPK Pathway for NRAS Mutant Melanoma: From Mechanism to Clinic.

  2025cites this paper
• ERK hyperactivation in epidermal keratinocytes impairs intercellular adhesion and drives Grover disease pathology.

  2024cites this paper
• Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature

  2024cites this paper
• Personalized therapy in oncology: melanoma as a paradigm for molecular-targeted treatment approaches

  2024cites this paper
• Trametinib, a MEK1/2 Inhibitor, Protects Mice from Cisplatin- and Noise-Induced Hearing Loss

  2024cites this paper
• Treatment of Metastatic Uveal Melanoma: Literature Review

  2024cites this paper
• Combined BET and MEK Inhibition synergistically suppresses melanoma by targeting YAP1

  2024cites this paper
• Pancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib

  2024cites this paper
• Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy

  2024cites this paper
• Population Pharmacokinetics of Trametinib and Impact of Nonadherence on Drug Exposure in Oncology Patients as Part of the Optimizing Oral Targeted Anticancer Therapies Study

  2024cites this paper
• FDA-Approved MEK1/2 Inhibitor, Trametinib, Protects Mice from Cisplatin and Noise-Induced Hearing Loss

  2024cites this paper
• Harnessing the role of aberrant cell signaling pathways in glioblastoma multiforme: a prospect towards the targeted therapy

  2024cites this paper
• ERK hyperactivation in epidermal keratinocytes impairs intercellular adhesion and drives Grover disease pathology

  2024cites this paper
• MAPK/ERK Activation in Macrophages Promotes Leishmania Internalization and Pathogenesis.

  2024cites this paper
• Human fetal brain self-organizes into long-term expanding organoids.

  2024cites this paper
• Utilization of Supervised Machine Learning to Understand Kinase Inhibitor Toxophore Profiles

  2023cites this paper
• Discovery of a novel ATP-competitive MEK inhibitor DS03090629 that overcomes resistance conferred by BRAF overexpression in BRAF-mutated melanoma.

  2023cites this paper
• Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients

  2023cites this paper
• First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations

  2023cites this paper
• Case report: Visibly curative effect of dabrafenib and trametinib on advanced thyroid carcinoma in 2 patients

  2023cites this paper
• Tebentafusp: a first-in-class treatment for metastatic uveal melanoma

  2023cites this paper
• Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study

  2023cites this paper
• The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer

  2023cites this paper
• Title : MAPK / ERK Activation in Macrophages Promotes Leishmania 1 Internalization and Pathogenesis 2 3 Running title : ERK 1 / 2 facilitates Leishmania internalization

  2023cites this paper
• High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma

  2023cites this paper
• MicroRNA-708 emerges as a potential candidate to target undruggable NRAS

  2023cites this paper
• Management of Uveal Melanoma: Updated Cancer Care Alberta Clinical Practice Guideline

  2023cites this paper
• Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies

  2023cites this paper
• NF1 alterations in cancers: therapeutic implications in precision medicine

  2023cites this paper
• Metastatic uveal melanoma complete response with nivolumab: A case report

  2023influential citation
• Trametinib-Induced Epidermal Thinning Accelerates a Mouse Model of Junctional Epidermolysis Bullosa

  2023cites this paper
• Age Is Just a Number: Progress and Obstacles in the Discovery of New Candidate Drugs for Sarcopenia

  2023cites this paper
• Activation of NFAT by HGF and IGF-1 via ARF6 and its effector ASAP1 promotes uveal melanoma metastasis

  2023cites this paper
• Targeting SERCA2 in organotypic epidermis reveals MEK inhibition as a therapeutic strategy for Darier disease

  2023cites this paper
• Targeting up-regulated cIAP2 in SOX10-deficient drug tolerant melanoma.

  2023cites this paper
• Targeting SERCA2 in organotypic epidermis reveals MEK inhibition as a therapeutic strategy for Darier disease

  2023cites this paper
• Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling

  2022cites this paper
• Cautious Addition of MEK Inhibitors to PD-1 Antibody Treatment in Patients with NRAS or NF1 Mutant Metastatic Melanoma Failing Initial Immunotherapy

  2022cites this paper
• Employing CRISPR-Cas9 to Generate CD133 Synthetic Lethal Melanoma Stem Cells

  2022cites this paper
• Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib

  2022cites this paper
• Trametinib for Painful Glomus Tumors in a Patient with Neurofibromatosis Type 1

  2022cites this paper
• NRAS mutation in differentiated thyroid cancer

  2022cites this paper
• Association of bilateral pan-uveitis with the use of trametinib for Langerhans cell histiocytosis.

  2022cites this paper
• Metastatic uveal melanoma: The final frontier.

  2022cites this paper
• A novel 7 RNA-based signature for prediction of prognosis and therapeutic responses of wild-type BRAF cutaneous melanoma

  2022cites this paper
• Use of Trametinib in Children and Young Adults With Progressive Low-grade Glioma and Glioneuronal Tumors

  2022cites this paper
• Functionalization of Nanomaterials for Skin Cancer Theranostics

  2022cites this paper
• Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ–focal adhesion kinase signaling circuitry

  2022cites this paper
• MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas

  2022cites this paper
• Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma

  2022cites this paper
• CERN Large Hadron Collider (LHC) Radiation Source for Magnetic Resonance Biospectroscopy in Metabolic and Molecular Imaging and Diagnosis of Cancer

  2022cites this paper
• Design and biological characterization of a series of dual mechanism ERK1/2 inhibitors with a Triazolopyridinone core

  2022cites this paper
• Targeted Therapy for Melanomas Without BRAF V600 Mutation

  2022cites this paper
• BRD4 inhibitor suppresses melanoma metastasis via the SPINK6/EGFR-EphA2 pathway.

  2022cites this paper
• Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy

  2022cites this paper
• The OSUMMER lines: a series of ultraviolet-accelerated NRAS-mutant mouse melanoma cell lines syngeneic to C57BL/6

  2022cites this paper
• Novel Treatments of Uveal Melanoma Identified with a Synthetic Lethal CRISPR/Cas9 Screen

  2022cites this paper
• Mechanical Properties of the Extracellular Environment of Human Brain Cells Drive the Effectiveness of Drugs in Fighting Central Nervous System Cancers

  2022cites this paper
• Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience

  2022cites this paper
• GNAQ and GNA11 Genes: A Comprehensive Review on Oncogenesis, Prognosis and Therapeutic Opportunities in Uveal Melanoma

  2022cites this paper
• Trametinib for refractory chylous effusions and systemic complications in children with Noonan syndrome.

  2022cites this paper
• Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study

  2022cites this paper
• Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma

  2022cites this paper
• A Genome-wide screen identifies PDPK1 as a target to enhance the efficacy of MEK1/2 inhibitors in NRAS mutant melanoma.

  2022cites this paper
• Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials

  2022cites this paper
• BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis

  2022cites this paper
• Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma.

  2022cites this paper
• Biology of Melanoma.

  2021cites this paper
• Genetic Landscape and Emerging Therapies in Uveal Melanoma

  2021cites this paper
• New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review

  2021cites this paper
• OTT_A_278095 3709..3719

  2021cites this paper
• Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy

  2021cites this paper
• Systemic Therapy for Metastatic Uveal Melanoma

  2021cites this paper
• Malignant spindle cell tumors of the posterior fossa in children: case series and review of management.

  2021cites this paper
• ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors

  2021cites this paper
• Molecular Markers and Targets in Melanoma

  2021cites this paper
• S-100-negative, GNA11 mutation-positive intramedullary meningeal melanocytoma of the thoracic spine: A radiographic challenge and histologic anomaly

  2021cites this paper
• Long-Term Maintained Response to Selective Internal Radiation Therapy in an Oligometastatic Uveal Melanoma Patient Treated with Concomitant Anti-PD-1 Therapy

  2021cites this paper
• Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma

  2021cites this paper
• KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.

  2021cites this paper
• Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches

  2021cites this paper
• Uveal Melanoma: Biology and Management

  2021cites this paper
• Dabrafenib and Trametinib

  2021cites this paper
• Development of new therapeutic options for the treatment of uveal melanoma

  2021cites this paper
• Intraocular and Orbital Cancers

  2021cites this paper
• Nonsurgical Management of Melanoma Brain Metastasis: Current Therapeutics, Challenges, and Strategies for Progress.

  2021cites this paper